NDAINJECTIONINJECTABLE
Approved
Feb 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ORABLOC (articaine hydrochloride and epinephrine bitartrate) by Pierre Fabre is anesthetic. First approved in 2010.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORABLOC is a local anesthetic combination of articaine hydrochloride and epinephrine bitartrate administered by injection for dental and oral procedures. It blocks nerve impulse generation and conduction while epinephrine acts as a vasoconstrictor to prolong anesthetic effect by slowing systemic absorption. The drug is indicated for infiltration anesthesia and nerve blocks in oral and maxillofacial surgery.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); teams should prepare for generic transition and defend market share through formulation differentiation or niche positioning.
Mechanism of Action
anesthetic. Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. In general, the progression…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ORABLOC represents 221 linked job opportunities primarily in R&D and Commercial functions, with notable emphasis on supply chain and manufacturing optimization roles typical of mature products approaching generic competition. Careers on this product involve defending market position through operational excellence, regional brand management in dental markets, and preparing organizational transitions for post-LOE competitive strategies.
Candidatures spontanées
Worked on ORABLOC at Pierre Fabre? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.